DGNOF (Diagnos) ROE % Adjusted to Book Value: -9.03% (As of Mar. 2026)


DGNOF Diagnos Inc DGNOF
16 GF Score
Price $0.18
GF Value $0.05
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Diagnos ROE % Adjusted to Book Value?

Diagnos DGNOF +1.00% 16 ROE % Adjusted to Book Value is -9.03% as of Mar. 2026. GuruFocus rates DGNOF with a GF Score™ of 16/100 and a GF Value™ of $0.05 (Significantly Overvalued). The stock has 5 warning signs investors should review.

Diagnos's ROE % for the quarter that ended in Mar. 2026 was -435.58%. Diagnos's PB Ratio for the quarter that ended in Mar. 2026 was 48.23. Diagnos's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 was -9.03%.

Diagnos ROE % Adjusted to Book Value Related Terms

Diagnos ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for Diagnos's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Diagnos ROE % Adjusted to Book Value Chart

Diagnos Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 -20.77

Diagnos Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 -9.03

DGNOF vs VEEV, BTSG, TEM: ROE % Adjusted to Book Value Comparison

For the Health Information Services subindustry, Diagnos's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Diagnos ROE % Adjusted to Book Value vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Diagnos's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Diagnos's ROE % Adjusted to Book Value falls into.


DGNOF
16GF Score
Diagnos Inc DGNOF
ROE % Adjusted to Book Value is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Diagnos ROE % Adjusted to Book Value Calculation

Diagnos's ROE % Adjusted to Book Value for the fiscal year that ended in Mar. 2026 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-1,001.51% / 48.23
=-20.77%

Diagnos's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-435.58% / 48.23
=-9.03%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of -9.03% mean?
Diagnos (DGNOF) has a ROE % Adjusted to Book Value of -9.03% as of Mar. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Diagnos and its competitors.
Is Diagnos' ROE % Adjusted to Book Value too high?
Diagnos' current ROE % Adjusted to Book Value is -9.03%. Overall, Diagnos has a GF Score™ of 16/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Diagnos' ROE % Adjusted to Book Value compare to VEEV and BTSG?
Diagnos' ROE % Adjusted to Book Value of -9.03% can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Healthcare Providers & Services company?
A good ROE % Adjusted to Book Value depends on the Healthcare Providers & Services industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Diagnos and its competitors. Diagnos's current ROE % Adjusted to Book Value is -9.03%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Diagnos stock overvalued right now?
Based on GuruFocus' analysis, Diagnos (DGNOF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.05, compared to a current price of $0.18 — trading 253.9% above its estimated fair value. The current ROE % Adjusted to Book Value is -9.03%. Diagnos' overall GF Score™ is 16/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Diagnos (DGNOF), the current ROE % Adjusted to Book Value is -9.03% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Diagnos (DGNOF) Overvalued in 2026?

Based on GuruFocus' analysis, Diagnos stock appears to be overvalued. The current stock price of $0.18 is trading 253.9% above its estimated GF Value™ of $0.05. GuruFocus considers Diagnos to be Significantly Overvalued.

Key valuation signals for DGNOF:

  • ROE % Adjusted to Book Value: -9.03%
  • GF Value™: $0.05 vs. price of $0.18 (253.9% above fair value)
  • GF Score™: 16/100 with 5 warning signs

No single metric tells the full story. See the DGNOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Diagnos Business Description

Other Exchanges ADK:Canada
Address 7005 Taschereau Boulevard, Suite 265, Brossard, Longueuil, QC, CAN, J4Z 1A7
Diagnos Inc is engaged in the provision of software-based interpretation services to assist health specialists in the detection of diabetic retinopathy. The company provides image analysis services through CARA (Computer Assisted Retinal Analysis). It operates in a single business segment of Healthcare services. The company has a business presence in Canada, United States of America, Mexico, Chile and others. The company's key revenue is derived from Canada.
16GF Score

Get the complete analysis for DGNOF

ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.18
Price
$0.05
GF Value